Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant)

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder of the human motor system. Neuroinflammation appears to be an important modulator of disease progression in ALS. Specifically, reduction of regulatory T cell (Treg) levels, along with an increase in...

Descripción completa

Detalles Bibliográficos
Autores principales: Vucic, Steve, Ryder, Julie, Mekhael, Linda, RD, Henderson, Mathers, Susan, Needham, Merilee, DW, Schultz, MC, Kiernan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
3700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015658/
https://www.ncbi.nlm.nih.gov/pubmed/32028398
http://dx.doi.org/10.1097/MD.0000000000018904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015658/
https://www.ncbi.nlm.nih.gov/pubmed/32028398
http://dx.doi.org/10.1097/MD.0000000000018904

Ejemplares similares